Kolexia
Besse Benjamin Oncologie médicale
Besse Benjamin
Oncologie médicale
Gustave-Roussy
Villejuif, France
1.1 K Activités
8.7 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Métastase tumorale Carcinomes Thymome Tumeurs du thymus Tumeurs du cerveau Adénocarcinome

Collaborateurs

Voir plus
Planchard David
Planchard David
Gustave-Roussy, Villejuif, France
Soria Jean-Charles
Soria Jean-Charles
Gustave-Roussy, Villejuif, France
Mezquita Perez Laura
Mezquita Perez Laura
Gustave-Roussy, Villejuif, France
Barlesi Fabrice
Barlesi Fabrice
Gustave-Roussy, Villejuif, France

Industries

Voir plus
Regeneron
18 collaboration(s)
Dernière en 2023
Chugai
12 collaboration(s)
Dernière en 2023
Syneos Health, LLC
4 collaboration(s)
Dernière en 2022
MSD
4 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
Essai Clinique (National Cancer Institute)   21 mars 2024
A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma: An Open-Label, Single Arm, Multicenter Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma
Essai Clinique (Roche)   20 mars 2024
HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON).
Essai Clinique (AstraZeneca)   14 mars 2024
Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer: A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib in Refractory Advanced Thymic Carcinoma
Essai Clinique (Dwight Owen)   12 mars 2024
KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma: A Phase 2, Open-Label, Multi-Center Study to Evaluate Efficacy, Safety and Tolerability of KN046 in Subjects With Thymic Carcinoma
Essai Clinique (Jiangsu Alphamab Biopharmaceuticals Co., Ltd)   10 mars 2024
A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1): A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)
Essai Clinique (Nuvalent Inc.)   07 mars 2024
HER2: A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients With HER2 Mutant Non-Small Cell Lung Cancer
Essai Clinique (Enliven Therapeutics)   01 mars 2024
LIBRETTO-001: A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Essai Clinique (Loxo Oncology, Inc.)   01 mars 2024
MARIPOSA: A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Essai Clinique (Janssen)   27 février 2024
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
Essai Clinique (Loxo Oncology, Inc.)   27 février 2024